Zydus Lifesciences gets USFDA nod for heart failure treatment drug

Zydus Lifesciences Ltd on Wednesday said it has received final approval from US health regulator to market its generic Sacubitril and Valsartan tablets combination used to treat chronic heart failure in ults.

approval by US Food and Drug ministration (USFDA) is to market Sacubitril and Valsartan tablets of strengths 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Zydus Lifesciences said in a regulatory filing.

Sacubitril and Valsartan combination is used to treat chronic heart failure in ults to help reduce risk of death and hospitalisation.

drug will be manufactured at group's formulation manufacturing facility in Moraiya, Ahmedab, company ded.